Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZLAB 
Zai Lab Ltd (ZLAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ZLAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $56.15
1 Year Target Price $56.15
| 7 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.24% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.00B USD | Price to earnings Ratio - | 1Y Target Price 56.15 |
Price to earnings Ratio - | 1Y Target Price 56.15 | ||
Volume (30-day avg) 12 | Beta 1.03 | 52 Weeks Range 16.56 - 44.34 | Updated Date 08/15/2025 |
52 Weeks Range 16.56 - 44.34 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.41 | Actual -0.04 |
Profitability
Profit Margin -49.68% | Operating Margin (TTM) -49.92% |
Management Effectiveness
Return on Assets (TTM) -14.35% | Return on Equity (TTM) -28.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3371786204 | Price to Sales(TTM) 9.36 |
Enterprise Value 3371786204 | Price to Sales(TTM) 9.36 | ||
Enterprise Value to Revenue 7.88 | Enterprise Value to EBITDA -2.35 | Shares Outstanding 111271000 | Shares Floating 1084438427 |
Shares Outstanding 111271000 | Shares Floating 1084438427 | ||
Percent Insiders 1.41 | Percent Institutions 43.53 |
Upturn AI SWOT
Zai Lab Ltd
Company Overview
History and Background
Zai Lab Ltd. was founded in 2013 and is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for oncology, autoimmune, infectious diseases and central nervous system diseases, in order to address unmet medical needs globally.
Core Business Areas
- Oncology: Focuses on developing and commercializing therapies for various cancer types.
- Autoimmune Diseases: Focuses on therapies for autoimmune diseases.
- Infectious Diseases: Developing therapeutics for Infectious diseases such as COVID
- Central Nervous System: Developing therapeutics for Central Nervous System diseases
Leadership and Structure
Samantha Du is the founder, Chairperson and CEO. The company has a board of directors and a management team overseeing operations across its therapeutic areas.
Top Products and Market Share
Key Offerings
- Niraparib (ZEJULA): An oral PARP inhibitor for the treatment of ovarian cancer. Zai Lab has the rights to develop and commercialize this drug in Greater China. Competitors include Lynparza (AZN), Rubraca (CLVS).
- Optune: A device for the treatment of glioblastoma. Zai Lab has commercialization rights for Optune in Greater China. Competitor is standard chemo and radiation therapy
- Efgartigimod alfa-fcab (VYVGART): A therapy for generalized myasthenia gravis (gMG). Zai Lab has the rights to develop and commercialize efgartigimod in Greater China. Competitors are Soliris (ALXN), Ultomiris (AZN) and immunosuppressants.
- Sulbactam-durlobactam (XERDURVO): A combination antibiotic therapy for infections caused by Acinetobacter baumannii-calcoaceticus complex. Zai Lab has global rights to develop and commercialize. Competitors are other antibiotics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense research and development, high regulatory hurdles, and significant market competition. Demand for innovative medicines continues to grow, driven by aging populations and increased healthcare spending.
Positioning
Zai Lab is positioned as a bridge between Western biopharmaceutical innovation and the Chinese market. Its competitive advantages include a strong understanding of the Chinese regulatory landscape and commercialization capabilities.
Total Addressable Market (TAM)
The global pharmaceutical market is expected to reach over $1.7 trillion by 2027. Zai Lab targets specific sub-segments, focusing on oncology, autoimmune, and infectious diseases in China and globally. TAM for these segments are estimated to be in the hundreds of billions of dollars. Zai Lab aims to capture a significant share through strategic partnerships and in-house development.
Upturn SWOT Analysis
Strengths
- Strong presence in China
- Diverse portfolio of innovative drugs
- Experienced management team
- Strategic partnerships with global biopharmaceutical companies
Weaknesses
- Reliance on licensing and partnerships
- High R&D expenses
- Relatively small revenue base compared to larger competitors
- Geographic concentration in China, political risk
Opportunities
- Expanding into new therapeutic areas
- Further penetration of the Chinese market
- Potential for global expansion
- Acquiring or licensing additional innovative products
Threats
- Regulatory changes in China
- Increased competition from domestic and international players
- Pricing pressures on pharmaceuticals
- Intellectual property risks
Competitors and Market Share
Key Competitors
- AZN
- MRK
- BMY
- GILD
Competitive Landscape
Zai Lab faces competition from both multinational pharmaceutical companies and domestic Chinese players. Its competitive advantages include its focus on innovative therapies and its strong presence in the Chinese market.
Major Acquisitions
None
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Zai Lab has experienced rapid revenue growth in recent years, driven by the commercialization of its key products.
Future Projections: Analysts project continued revenue growth for Zai Lab, driven by new product launches and geographic expansion. Profitability remains a key focus area.
Recent Initiatives: Recent initiatives include expanding partnerships, advancing clinical trials, and strengthening commercialization capabilities in China.
Summary
Zai Lab is a commercial-stage biopharmaceutical company with a strong presence in China, however Zai Lab is still growing and has yet to establish solid profitability. Its diverse portfolio and strategic partnerships are working well in its favor and positioning it for further growth in the market. Political risk and regulations, as well as increasing competition, represent future challenges and threats that the company will need to manage. Further penetration into the China market will be essential for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Industry Reports, Financial News Articles, Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on publicly available information and may be subject to change. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zai Lab Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-09-20 | Founder, Chairperson & CEO Dr. Ying Du Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1869 | Website https://www.zailaboratory.com |
Full time employees 1869 | Website https://www.zailaboratory.com | ||
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.